雀巢集团（以下简称"集团"）于2026年2月19日发布2025年业绩。报告显示，集团2025 年有机增长率 （OG）达 3.5%，基础交易营业利润率（UTOP）为16.1%的，净利润为90亿瑞士法郎，并创造了92亿瑞 士法郎的自由现金流。 集团针对性的增长投资有效推动实际内部增长率从2025年上半年的0.2% 加速提升至下半年的1.4%，各 品类及大区均实现改善。集团销量市场份额目前已企稳，且增长势头延续至2025年第四季度，该季度有 机增长率为4.0%。"十亿俱乐部"品牌市场份额增长由负转正，创下十多年来的最佳表现。大中华区受渠 道库存调整的影响减弱，第四季度有机增长率较前两个季度有所改善。 第二，以实际内部增长率拉动的业务增长为核心。集团将高潜力增长平台的业务规模扩大至占集团销售 额的30%，实现高个位数增长，并将在2026年获得6亿瑞士法郎额外投资支持；升级并进一步强化消费 者洞察、创新及营销能力之间的衔接。 第三，加速业务转型。集团简化组织架构，并强化本地责任制，提升决策效率与响应速度；同时加速推 进成本优化举措，白领岗位运营效率提升方面已提前达成目标，实现了10亿瑞士法郎年度节约目标中的 20%。 ...

Investment Rating - The report maintains an "Overweight" rating for the food and beverage industry [9] Core Insights - The report highlights a structural differentiation in consumer recovery across various segments, with high-end consumption showing signs of recovery while mid-range and mass-market segments lag behind [1] - Foreign brands are facing challenges due to weak demand and a trend towards "de-branding," which has led to overall performance pressure [1] - Companies achieving growth are primarily relying on their own brand strength and channel strategies [1] Alcoholic Beverages - The overseas spirits giants are experiencing performance pressure in China, with Pernod Ricard and Diageo reporting significant declines in sales [2][13] - Diageo's management remains cautious, expecting continued challenges in the market, particularly in the white liquor segment [2][14] - Rémy Cointreau's sales in China have stabilized, but internal performance shows structural differentiation [2][15] Dairy Products - Foreign brands in the dairy sector, particularly in milk beverages and nutritional products, are performing well due to strong brand management and product innovation [3][22] - The market for dairy products is expected to continue growing, especially in segments like low-temperature fresh milk and cheese [3][32] - The high import dependency in certain dairy categories presents opportunities for domestic alternatives [3][32] Soft Drinks - The soft drink industry is experiencing varied performance across segments, with carbonated drinks under pressure while energy drinks and sugar-free tea are expanding [4][33] - Coca-Cola and PepsiCo maintain high market shares in carbonated drinks but face increasing competition from local brands [4][33] - Monster's sales in China are growing rapidly, indicating a positive outlook for the energy drink segment [4][44] Beer - The beer market is under pressure due to weakened dining demand, with Budweiser experiencing a significant decline in sales [5] - Carlsberg has stabilized its performance through product adjustments, while Heineken benefits from partnerships with local brands [5] Snacks - The snack sector is seeing a weak recovery, with foreign brands struggling against local competitors [6] - Mondelez has managed to maintain steady growth in China through localized marketing strategies [6] Condiments - Foreign condiment brands are focusing on improving product value and adapting to changing consumer preferences [7] - The market is shifting towards value-oriented consumption, prompting companies to adjust their strategies [7]

Financial Data and Key Metrics Changes - The company reported fourth quarter adjusted earnings per share (EPS) of $0.87 and full year adjusted EPS of $3.43, with total segment operating profit of $821 million for the fourth quarter and $3.2 billion for the full year [4] - The trailing fourth quarter adjusted return on invested capital (ROIC) was 6.3%, and cash flow from operations before working capital changes was $2.7 billion for 2025, with a $1.5 billion cash flow benefit from inventory reduction [4][19] Business Line Data and Key Metrics Changes - The Ag Services and Oilseeds (AS&O) segment operating profit for the fourth quarter was $444 million, down 31% year-over-year, and for the full year, it was $1.6 billion, a 34% decrease compared to 2024 [11] - The Carbohydrate Solutions segment operating profit for the fourth quarter was $299 million, down 6% year-over-year, and for the full year, it was $1.2 billion, down 12% compared to 2024 [14] - The Nutrition segment revenues were $1.8 billion for the fourth quarter, remaining flat year-over-year, with human nutrition revenue increasing by 5% and animal nutrition revenue decreasing by 4% [16] Market Data and Key Metrics Changes - The operating environment throughout 2025 was challenging, with lower export activity from North America impacting the Ag Services subsegment [11] - The company expects positive economic opportunities for the industry and American farmers to materialize, which should drive additional long-term investments [9] Company Strategy and Development Direction - The company is focusing on five key growth areas: enhanced nutrition, biotics, biosolutions, precision fermentation, and decarbonization, with each presenting potential for compelling returns [7] - The company executed over 20 projects as part of portfolio optimization and simplification initiatives, achieving approximately $200 million in cost savings [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, anticipating a more constructive operating environment in 2026, driven by improved trade relations and expected clarity in U.S. biofuel policy [9][10] - The current outlook for adjusted EPS in 2026 is projected to be between $3.60 and $4.25, reflecting growth over 2025 [20] Other Important Information - The company paid its 376th consecutive quarterly dividend during the fourth quarter [5] - The joint venture with Alltech has commenced operations, although it is not expected to have a material impact on nutrition operating profit in 2026 [22] Q&A Session Summary Question: Congratulations on closing the case with the SEC and DOJ. What are the expectations for operating rates and processing rates of biodiesel and renewable diesel facilities once the RVO arrives? - Management acknowledged the difficulty in providing guidance due to external factors but expressed optimism about positive impacts once clarity is received on policies [30][31] Question: Can you provide an update on the Nutrition segment and the recovery of customers lost during the Decatur East downtime? - Management indicated that while there was a strong performance in flavors, recovery of customer demand is ongoing and will take time [39][40] Question: What are the expectations for crush margins and the impact of RVO policy on future earnings? - Management stated that the timing and adoption of RVO policy will significantly influence crush margins and overall earnings, with a cautious outlook provided [58][60] Question: What is driving the weakness in Starches and Sweeteners demand? - Management noted that consumer behavior changes, including the adoption of GLP-1 medications, have contributed to reduced demand, alongside pricing pressures [64][66]

Core Insights - The trend of consumers bringing screenshots to stores signifies a maturation in the maternal and infant consumption market and presents an opportunity for offline stores to redefine their value proposition [1][2] Consumer Behavior Changes - Consumers are increasingly entering stores with screenshots from platforms like Xiaohongshu, short video sites, and e-commerce reviews, rather than asking for recommendations [2][4] - Over 90% of maternal and infant consumers conduct proactive information research before purchasing, with content platforms and user reviews becoming key information sources [4] - The nature of screenshots has shifted from promotional content to real user evaluations, ingredient comparisons, and even negative reviews, indicating a focus on evidence to minimize decision-making risks [4][5] Decision-Making Dynamics - The decision-making process has evolved, with consumers now seeking confirmation rather than recommendations, reflecting a shift in decision-making power towards consumers [4][5] - Consumers are more cautious and professional in their inquiries, often asking about differences, version consistency, and ingredient adjustments rather than simply asking for the best option [5] Implications for Retail - The role of stores and sales associates is changing from being mere recommenders to verification points, as consumers arrive with pre-formed judgments seeking validation [5][7] - The industry faces a challenge in providing new value propositions after consumers have completed their initial judgments externally [7]

Core Viewpoint - The stock price of New Harmony has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 77.33 billion yuan. The company has shown mixed performance in terms of stock price changes over different time frames [1]. Financial Performance - For the period from January to September 2025, New Harmony achieved a revenue of 16.642 billion yuan, representing a year-on-year growth of 5.45%. The net profit attributable to shareholders was 5.321 billion yuan, reflecting a significant increase of 33.37% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for New Harmony increased to 82,500, up by 2.15%. The average circulating shares per person decreased by 2.11% to 36,823 shares [2]. - The company has distributed a total of 16.114 billion yuan in dividends since its A-share listing, with 5.682 billion yuan distributed over the past three years [3]. Major Shareholders - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 185 million shares, which is a decrease of 6.6675 million shares from the previous period. Other notable shareholders include various ETFs, all of which have seen a reduction in their holdings [3].

Core Viewpoint - New Hope's stock price has shown a positive trend with a year-to-date increase of 2.50% and a significant rise of 10.96% over the past 60 days, indicating strong market interest and performance [1]. Financial Performance - For the period from January to September 2025, New Hope achieved a revenue of 16.642 billion yuan, reflecting a year-on-year growth of 5.45%. The net profit attributable to shareholders reached 5.321 billion yuan, marking a substantial increase of 33.37% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for New Hope increased to 82,500, up by 2.15%. The average number of circulating shares per shareholder decreased by 2.11% to 36,823 shares [2]. - The company has distributed a total of 16.114 billion yuan in dividends since its A-share listing, with 5.682 billion yuan distributed over the past three years [3]. Major Shareholders - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 185 million shares, which is a decrease of 6.6675 million shares from the previous period. Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which have also seen reductions in their holdings [3].

Group 1 - The article discusses the changes in the shareholding structure of various companies, highlighting the movements of major shareholders and their respective holdings [1][2][3] - Notable changes include the increase in holdings by certain strategic funds, such as 重阳战略, which have maintained or increased their stakes in companies like 002001 and 002352 [1][2] - The data indicates that some companies have seen fluctuations in their top shareholders, with some being pushed out of the top ten due to changes in share distribution among existing shareholders [3] Group 2 - The report provides specific figures on shareholdings, such as 5407.22 million shares held by 重阳战略汇智 in 002001, representing 1.75% of the total [2] - It also notes that certain companies, like 移运通信, have seen new entries into their top shareholder lists, indicating potential shifts in investor confidence or strategic realignments [1][3] - The overall market sentiment appears to reflect a cautious approach, with some shareholders opting to maintain their positions rather than increase their stakes significantly [2][3]

Core Viewpoint - JD Health (06618) is expected to outperform market expectations in the second half of 2025, driven by a surge in flu cases leading to increased demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's stock rose over 6%, reaching HKD 62 with a trading volume of HKD 411 million [1] - Nomura forecasts that JD Health's revenue for Q4 2025 will reach RMB 20 billion, representing a year-on-year growth of 22% [1] - The growth in Q4 2025 is attributed to sales increases in pharmaceuticals (30%), nutritional products (20%), and medical devices (10%) [1] Group 2: Market Trends - The increase in flu cases in Q4 2025 is expected to significantly boost pharmaceutical sales, contributing a high single-digit percentage to total sales [1] - The sales of medical devices, such as home oxygen concentrators, are also anticipated to rise due to the flu season [1] - Nutritional brands will continue effective marketing campaigns in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - CICC noted strong revenue performance for JD Health in 2025, with quarterly growth rates around 25% year-on-year for Q1 to Q3 [1] - The company has signed strategic cooperation agreements with pharmaceutical companies like Eli Lilly, Innovent Biologics, and Bayer China, enhancing its unique business model of launching new drugs online [1] - The ongoing trend of increasing original drug volumes is expected to support strong revenue performance in Q4 2025 [1]

Core Viewpoint - JD Health is expected to outperform market expectations in the second half of 2025, primarily due to a surge in flu cases driving up demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's revenue for Q4 2025 is projected to reach 20 billion RMB, representing a year-on-year growth of 22%, driven by sales growth in pharmaceuticals, nutritional products, and medical devices at 30%, 20%, and 10% respectively [1] - The company has shown strong revenue performance throughout 2025, with each quarter from Q1 to Q3 achieving approximately 25% year-on-year growth [1] - The overall revenue growth for JD Health in 2025 is anticipated to be close to 25% year-on-year [1] Group 2: Market Dynamics - The increase in flu cases in Q4 2025 is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - The sales of medical devices, such as home oxygen concentrators, are also expected to rise due to the flu outbreak [1] - JD Health's nutritional brands will continue to implement effective marketing strategies in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - JD Health has signed strategic cooperation agreements with pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China, enhancing its business model of launching new drugs online [1]

消息面上，野村发表报告，预计京东健康2025年下半年业绩将好过市场预期，主要因2025年第四季流感 病例激增带动药品需求上升。该机构预估京东健康2025年第四季营收将达200亿元人民币，按年增长 22%，受惠来自药品/营养品/医疗器材业务分别实现30%、20%及10%按年销售增长。2025年第四季流感 病例扩散带动相关药品，占药品销售额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同 时，营养品牌在2025年第四季持续推行有效营销活动，强化其稳健增长态势。 中金发布研报称，考虑到原研品类放量趋势依旧且流感品种需求强劲，上调京东健康25年及26年收入预 测2%至725亿元及817亿元，同时考虑毛利率改善趋势及潜在利息收入波动的综合影响，该行分别上调 25年及26年non-IFRS净利润4%及1%至65亿元及64亿元。首次引入27年收入预测912亿元及non-IFRS净 利润预测68亿元。考虑到近期板块表现略有波动，基于SOTP维持目标价71.4港币不变(23%上行空间)， 维持跑赢行业评级。 金吾财讯 | 京东健康(06618)股价上行，截至发稿，涨5.58%，报61.45港元，成交额2.3亿港元。 消息 ...